Description

1-[2-Deoxy-3,5-Di-o-(p-Chlorobenzoyl)-β-D-Erythropentofuranosyl]-5-Trifluoromethyl Uracil is a sophisticated nucleoside analog intermediate of significant interest in advanced pharmaceutical research and development. This compound is valued for its role as a key building block in the synthesis of novel antiviral and anticancer agents, particularly those targeting viral polymerases. It is primarily sought after by research institutions, pharmaceutical R&D departments, and fine chemical manufacturers engaged in the development of next-generation therapeutics.

Application

• Pharmaceutical Intermediate: A critical precursor in the synthesis of novel nucleoside-based antiviral drugs.
• Antiviral Agent Research: Used in the development of compounds targeting herpesviruses, hepatitis viruses, and other DNA viruses.
• Oncology Research: Serves as a building block for potential anticancer prodrugs and targeted therapies.
• Biochemical Tool: Employed in enzymatic studies to investigate polymerase inhibition mechanisms.
• Process Chemistry: Utilized in scale-up and optimization studies for the commercial production of active pharmaceutical ingredients (APIs).
• Custom Synthesis: A starting material for the preparation of labeled compounds (e.g., deuterated, C13) for metabolic and pharmacokinetic studies.

Basic Information

Product Name	1-[2-Deoxy-3,5-Di-o-(p-Chlorobenzoyl)-β-D-Erythropentofuranosyl]-5-Trifluoromethyl Uracil
CAS No.	129664-47-7
Molecular Formula	C25H19Cl2F3N2O7
Molecular Weight	587.33 g/mol
Synonyms	5-Trifluoromethyl-2'-deoxyuridine 3',5'-di-p-chlorobenzoate; 5-Trifluoromethyl-2'-deoxyuridine 3',5'-bis(4-chlorobenzoate); 1-(2-Deoxy-3,5-di-O-(4-chlorobenzoyl)-β-D-erythro-pentofuranosyl)-5-(trifluoromethyl)uracil; 5-CF3-dUrd 3',5'-di-(p-Cl-Bz); Trifluridine 3',5'-di-p-chlorobenzoate (protected intermediate); 2'-Deoxy-5-(trifluoromethyl)uridine 3',5'-bis(4-chlorobenzoate); 5-Trifluoromethyl-2'-deoxyuridine 3',5'-di(4-chlorobenzoate)
EINECS	Contact for details

Quality Control

Our 1-[2-Deoxy-3,5-Di-o-(p-Chlorobenzoyl)-β-D-Erythropentofuranosyl]-5-Trifluoromethyl Uracil is produced under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation via NMR and mass spectrometry, to ensure it meets the high standards required for pharmaceutical research. Certificates of Analysis (COA) detailing purity, impurity profile, and other critical parameters are available upon request to support your regulatory and R&D documentation.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound is light-sensitive (store away from light). Keep the container tightly sealed in a dry environment to minimize moisture exposure.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms
Identification (NMR)	Conforms
Purity (HPLC)	≥ 98.0%
Single Maximum Impurity	≤ 1.0%
Total Impurities	≤ 2.0%
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Complies with ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.